FGFR1 and neoplasm: Importantly, given the association between enhanced stemness and FGFR1-induced palbociclib resistance, our results also suggest that assessment of various strategies targeting FGFR deregulation-associated CDKi resistance should include biomarkers that can evaluate CSC stemness in tumor treatment.